Telomerase is a regulated enzyme and its activity is tightly associated with cell proliferation. The mechanisms of this association are unclear, but speci®c growth factors may regulate telomerase activity. The present study examines the eect of epidermal growth factor (EGF) on telomerase activity and identi®es the signal transduction pathway involved in this process. EGF upregulated telomerase activity in EGF receptor-positive cells after the activation of telomerase reverse transcriptase (TERT) mRNA expression. This activation was rapid, peaked after 6 or 12 h and was not blocked by the concurrent exposure to cycloheximide, suggesting a direct eect of EGF on TERT transcription. Transient expression assays revealed that EGF activates the hTERT promoter and that the proximal core promoter is responsible for this regulation. The activation of hTERT mRNA expression by EGF was speci®cally blocked by MEK inhibitor, and in vitro kinase assays demonstrated that ERK is activated in response to EGF. Transient expression assays using mutant reporter plasmids revealed that an ETS motif located in the core promoter of hTERT is required for the EGF-induced transactivation of hTERT. Overexpression of wild type Ets in cells enhanced the EGF eect on hTERT transcription, while that of dominant negative Ets signi®cantly repressed EGF action. These ®ndings suggest that EGF activates telomerase through the direct activation of TERT transcription, in which the Ras/ MEK/ERK pathway and Ets factor play major roles. Our data support the notion that growth factors directly regulate telomerase via speci®c signal transduction pathways.
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Introduction
Telomerase is a specialized RNA-dependent ribonucleoprotein polymerase that can restore telomere sequences at the ends of chromosomes (Greider, 1996) . Somatic cells lack telomerase activity. In these cells, telomeres progressively shorten with repeated cell division, leading to replicative senescence. Telomerase activation is required for the cells to overcome replicative senescence and to obtain immortal capacity, and is therefore a critical step in carcinogenesis. Human telomerase reverse transcriptase (hTERT) is a catalytic subunit of telomerase that bears the enzymatic activity of telomerase (Meyerson et al., 1997; Nakamura et al., 1997) . The expression of hTERT mRNA is closely associated with telomerase activity in cell lines and tumor samples from a variety of tissues (Takakura et al., 1998; Kyo et al., 1999) . Ectopic hTERT expression into normal cells confers telomerase activity and extend their life span Bornar et al., 1998) . These ®ndings suggest that hTERT is a critical determinant of telomerase activity.
Telomerase activity is tightly regulated at the transcriptional level of hTERT. We recently cloned the 5'-flanking sequence of the hTERT gene and identi®ed the 181-bp core promoter region essential for transcriptional activation of hTERT gene in cancer cells . Transcription factors that regulate hTERT transcription have been identi®ed, including c-Myc and Sp1, the binding sites for which are located within the core promoter of hTERT (Wu et al., 1999; Kyo et al., 2000) . The up-regulation of these factors may play crucial roles in hTERT activation during carcinogenesis. However, other factors involved in transcriptional regulation of hTERT have not been well de®ned.
Recent evidence shows that telomerase activity is closely associated with cell proliferation (Hiyama et al., 1995; Kyo et al., 1997) . Telomerase activity in cell lines is down-regulated under conditions that inhibit cell proliferation such as serum deprivation, and cells that exit from the cell cycle lose telomerase activity (Holt et al., 1996 Yang et al., 2000) . These ®ndings indicate that growth signals are directly or indirectly involved in telomerase regulation. In fact, some growth factors do regulate telomerase activity, such as FGF and IGF-1 (Haik et al., 2000; Tsumiki et al., 2000; Tu et al., 1999; Hiyama et al., 1995) . However, the molecular mechanisms of FGF and IGF-1-dependent telomerase regulation are not well understood.
Epidermal growth factor (EGF) stimulates the proliferation of a wide variety of cell types. The transduction pathways for EGF signals have been analysed in detail. The binding of ligand to EGF receptor (EGFR) induces receptor dimerization, followed by conformational changes that activate intrinsic tyrosine kinase, which sequentially lead to receptor autophosphorylation, the activation of several signal transduction pathways and the transcriptional activation of growth-related genes such as c-fos and c-jun (Ullrich and Schlessinger, 1990; Carpenter, 1992; Van der Geer et al., 1994) . To clarify the molecular mechanism of growth factor-dependent telomerase regulation, we examined the eect of EGF on telomerase activity in two types of cells with EGFR and analysed the signal transduction pathway involved in telomerase activation. We found that EGF activates telomerase through the up-regulation of hTERT expression. This is a direct action on the hTERT promoter via a speci®c signal transduction pathway in which the Ras/MEK/ERK pathway and Ets factor play major roles.
Results

Diverse effects of EGF on growth of NIH3T3 and A-431 cells
We examined the eect of EGF on the growth of telomerase-positive two cell lines. NIH3T3 cells were transfected with human EGF receptor (EGFR) cDNA and clones overexpressing EGFR were isolated for assay (Yamazaki et al., 1990) . A-431 cells are derived from a human vulvar cancer that constitutively expressed EGFR. The proliferation of NIH3T3 cells was stimulated by 20 ± 100 ng/ml EGF for 6 days ( Figure 1a ). In contrast, EGF inhibited the growth of A-431 cells by 75% 6 days after exposure to EGF (Figure 1b ). This inhibitory eect is due to the induction of p21 expression (Fan et al., 1995) . Thus, EGF exhibited diverse eects on cell growth that was dependent upon cell type.
EGF up-regulates telomerase through direct activation of hTERT transcription
We examined the eects of EGF on telomerase activity in the two cell lines. Cells were starved in serum-free media for 48 h and cultured in the presence or absence of EGF, then the TRAP assay was performed. Telomerase activity in both cell types was signi®cantly enhanced 24 h after exposure to EGF (Figure 2 ). We performed semiquantitative RT ± PCR to determine whether or not this activation was due to the upregulation of TERT expression. The expression of hTERT mRNA in A-431 cells was apparently increased by EGF (Figure 3a) . To examine whether this activation applies to other cell types, cervical cancer ME180 cells and breast cancer MCF-7 cells, both of which were con®rmed to be EGFR-and hTERT-positive, were treated with EGF, and hTERT mRNA expression was examined. EGF signi®cantly activated hTERT mRNA expression (Figure 3a ) in these cells, suggesting that the eect of EGF is not limited to A-431 cells. However, when hTERT-negative normal cells (normal foreskin ®broblasts or endometrial stromal cells) were treated with EGF, no induction of hTERT mRNA expression was observed (data not shown). Thus, the eect of EGF is limited to telomerase-positive cells that constitutively express hTERT and does not apply to hTERT-negative cells.
The activation of hTERT mRNA expression observed was rapid and peaked 6 or 12 h after exposure, and was not blocked by a concurrent incubation with cycloheximide ( Figure 3b ). The results obtained in NIH3T3 cells were similar (data not shown). The rapid kinetics of TERT mRNA expression as well as the independence of de novo protein synthesis are consistent with the direct eect of EGF on TERT expression. To further examine whether or not this is due to the transcriptional regulation of TERT gene, luciferase assays were performed in which A-431 cells were transfected with the hTERT-promoter reporter plasmids and incubated in the presence or absence of EGF. The transcriptional activity of the 3.3 kb fulllength promoter (pGL3-3328) was signi®cantly increased by EGF treatment (Figure 3c ), suggesting that EGF activates TERT mRNA expression via transcriptional up-regulation.
EGF activates hTERT transcription via the MAP kinase signaling pathway
Ligand binding to EGFR elicits intracellular signal transduction to activate the transcription of several growth-regulating genes. To identify the signaling pathway for EGF-induced hTERT transcription, A-431 cells were incubated with EGF in the absence or presence of speci®c inhibitors for each pathway, then RT ± PCR assays were performed ( Figure 4a ). The eect of EGF was signi®cantly inhibited by U0126, a specialized inhibitor of MEK. In contrast, Wortmannin, a PI3 kinase inhibitor, or SB203850, a p38 inhibitor, did not aect this activation. These ®ndings suggest that the Ras/MEK/ERK pathway is the major pathway involved in this regulation. To further con®rm this notion, we examined EGF-mediated ERK activation in A-431 cell lysates by in vitro kinase assays. Cells were incubated with EGF, lysed, extracted and immunoprecipitated with anti-ERK1 antibody. The activity of ERK kinase was evaluated by measuring its ability to phosphorylate its substrate protein, MBP. Figure 4b shows that the ERK kinase activity was signi®cantly enhanced by EGF. Similar activation was observed in NIH3T3 cells (data not shown). These ®ndings suggest that EGF activate hTERT mRNA expression through the MAP kinase cascades.
Identification of cis-and trans-elements of the TERT promoter involved in EGF-induced transactivation of hTERT MAP kinase signals are transmitted to target genes in which speci®c transcription factors are activated by phosphorylation and which interact with cis-elements on the promoter. To identify the cis-elements of the hTERT promoter involved in EGF-induced transactivation, luciferase assays were performed in which A-431 cells transfected with various 5'-deletion mutants of the hTERT-promoter reporter plasmid and incubated with or without EGF. Various 5'-deletions of full-length promoter from 73328 to 7181 did not signi®cantly aect responsiveness to EGF, and even the 181-bp core promoter (pGL3-181) responded to EGF stimulation (Figure 5b ). The most proximal 32-bp region (pGL3-32) sustained responsiveness to EGF, although basal transcriptional activity apparently decreased. Similar results were obtained in NIH3T3 cells (data not shown). The 181-bp core promoter and the proximal 77-bp 5'-UTR includes two E-boxes which are the binding motif of c-Myc, which is the target of MAP kinase (Seth et al., 1992; Gupta et al., 1993) . Furthermore, EGF activates the transcriptional ability of c-Myc via phosphorylation (Alvarez et al., 1991) . We therefore examined whether or not c-Myc sites are involved in the EGF-induced transactivation of hTERT. Abrogation of the E-box by substitution mutations in pGL3-181 did not aect responsiveness to EGF (Figure 5c ). The core promoter also includes multiple binding sites for Sp1, which plays important roles in EGF-signaling. Abrogation of all Sp1 binding sites by substitution mutations also did not aect responsiveness to EGF. These data suggest that neither c-Myc nor Sp1 transmit EGF signals onto the hTERT promoter. We also examined the involvement of other speci®c sites on hTERT promoter in EGF-induced transactivation. Some components of basal transcription complexes are activated by phosphorylation via speci®c signaling pathways (Dubois et al., 1994; Bonnet et al., 1999) . In TATA-less Figure 1 Growth curve of NIH3T3 cells expressing human EGF receptor or A-431 cells. Cells were starved in 0.5% FBS for 7 days prior to assay, then cultured in DMEM with 0.5% FBS with or without various concentrations of EGF for various periods. Cells were counted every 2 days Figure 2 Eects of EGF on telomerase activity. NIH3T3 cells expressing human EGFR or A-431 cells were starved in serumfree media for 48 h, then incubated with EGF for 24 to 48 h. Cells were then harvested and TRAP assays were performed. IC: internal control to verify the ampli®cation eciency of PCR promoters such as the hTERT promoter, basal transcriptional complexes bind to`initiator' sequences instead of to the TATA-box. We identi®ed two candidate sequences as initiators on the hTERT promoter at positions +13 and +43 (Figure 5a ). To examine the involvement of these sites in EGF-induced transactivation of hTERT, luciferase assays were performed using mutant reporter plasmids. Figure 5d shows that abrogation of each site did not aect responsiveness to EGF. Finally, we examined the involvement of another candidate site located at 723. This site is included in the 32-bp proximal promoter that was determined as the minimal responsive element for EGF, and which contains two consensus motifs side by side for Ets transcription factors (Figure 5a ). The Ets family is the major target of MAP kinase signaling (Hill and Treisman, 1995) . Luciferase assays using mutant reporter plasmids revealed that abrogation of Ets site signi®cantly reduced responsiveness to EGF (Figure 6a ). To con®rm that EGF signals are actually transmitted by Ets, expression vectors for wild-type Ets 2 (pRK5-ets-2) or truncated Ets-2 with dominant negative activity (pRK5-ets-2D1-328) were concurrently transfected with pGL3-32, then luciferase assays were performed. Overexpression of wild-type Ets signi®cantly enhanced EGF-induced transactivation, while that of dominant negative Ets signi®cantly blocked the EGF eects (Figure 6b) . Similar results were obtained in NIH3T3 cells with EGFR expression (data not shown). These ®ndings suggest that Ets is the major mediator involved in the EGF-induced transactivation of hTERT. , MCF-7 and NIH3T3 cells were starved in serum-free media for 24 h and incubated with EGF for various periods. Cells were harvested and RT ± PCR assays were performed to examine the expression of TERT mRNA. (b) To examine the dependency of de novo protein synthesis in EGF-induced regulation of hTERT, cycloheximide was added 30 min prior to EGF treatment. Twelve hours after the treatment with EGF, cells were harvested and RT ± PCR assays were performed to examine the expression of hTERT mRNA. CHX: Cycloheximide. (c) Eects of EGF on the transcriptional activity of hTERT. A-431 cells were transfected with hTERT promoterluciferase plasmids (pGL3-3328) and incubated in the presence or absence of EGF for 24 h, and then cells were harvested and luciferase assays were performed. Data is shown as relative luciferase activity. Luciferase activity in control samples transfected with pGL3-Control (SV40 enhancer/promoter-luciferase plasmid) was normalized to 1.0
Discussion
Several investigators have reported proliferation-dependent telomerase regulation. Holt et al. (1996 Holt et al. ( , 1997 examined telomerase activity in cells cultured in media with varying concentrations of serum and found that the rate of cell proliferation and the level of telomerase activity are closely related. Yang et al. (2000) also reported that telomerase activity in cells is suppressed by reagents that induce terminal dierentiation or by depleting serum, and that recovery from these conditions results in a prompt increase in telomerase activity followed by enhanced cell proliferation. These studies give rise to the question as to whether telomerase activation is merely a secondary event following to cell proliferation or whether speci®c signaling pathways are present for telomerase activation in response to growth stimulation. The present study used two cell lines to analyse the EGF-induced regulation of telomerase. EGF signi®cantly up-regulated the growth of NIH3T3 cells that overexpressed EFGR. In contrast, the growth of A-431 cells was inhibited in response to EGF. Nevertheless, EGF activated telomerase in both cell types. This activation was brought about by the upregulation of TERT mRNA expression, which occurred within 12 h after exposure when changes in cell proliferation were not apparent. Furthermore, the activation of TERT mRNA expression did not require de novo protein synthesis. These ®ndings are consistent with the direct eect of EGF on the TERT gene.
The MEK inhibitor, U0126 eectively blocked the activation of TERT mRNA expression by EGF. This is a speci®c, and not a toxic eect since other inhibitors for PI3K or p38 signaling pathways failed to block the activation. Furthermore, in vitro kinase assays revealed that EGF promptly activates ERK in A-431 cells. These ®ndings suggest that the Ras/MEK/ERK pathway plays major roles in EGF-induced telomerase activation, and that speci®c signaling pathways regulate telomerase activity in response to growth stimuli.
While the essential function of growth signals is to control cellular proliferation, they may also directly regulate telomerase activity via speci®c signaling pathways. The physiological signi®cance of such regulatory activities remains unclear, but rapid telomerase activation induced by growth signals might play roles in preventing extensive telomere erosion in proliferationcompetent cancer cells. The present study demonstrates that EGF acts on cells that constitutively express hTERT but not on normal cells that lack telomerase and hTERT expression. We therefore speculate that EGF-Ets pathway can enhance constitutive hTERT expression but is not essential for switch on/o mechanisms of hTERT expression.
Transient expression assays using various deletion mutants of luciferase reporters revealed that the proximal core promoter containing c-Myc and Sp1 sites is responsible for EGF-mediated transactivation. One report indicated that c-Myc is a substrate for phosphorylation by MAP kinase at Ser-62, and that the phosphorylation of these transactivation domains leads to the up-regulation of target gene expression (Gupta et al., 1993) . Based on these data, we ®rst examined whether or not c-Myc is involved in EGF signaling. However, neither deletion nor substitution mutations of c-Myc sites aected responsiveness to EGF, suggesting that c-Myc is not the major mediator of EGF-signaling. Another important factor acting on this region is Sp1. Chen and Chang (2000) reported that c-Jun and Sp1 cooperatively mediate the EGF-induced gene expression of human 12(S)-lipoxygenase in A-431 cells. That study found that cJun expression is activated by EGF via Raf-MEK-ERK signaling pathway and that protein-protein interaction of c-Jun with Sp1 is enhanced, with Sp1 functioning as a carrier that brings c-Jun to the promoter region. They proposed that the interaction between c-Jun and Sp1 plays important roles in the EGF-induced transactivation of TATA-less promoters. Our data, however, showed that Sp1 is not largely involved in this regulation. Instead, we found that the Ets factor mediates EGF-signaling to regulate TERT gene expression. The Ets family is a series of transcriptional factors targeted by ERK (Hill and Treisman, 1995) . The speci®c sequence of promoters recognized and bound by the Ets factor is (T/A)TTCC(T/G), named the ETS motif (Wasylyk et al., 1990) . The hTERT promoter contains two ETS motifs at 723 and 718. Figure 6a shows that abrogation of the ETS motif resulted in a signi®cant loss of EGF eects. EGF stimulation was signi®-cantly enhanced by the overexpression of wild-type Ets, but inhibited by the dominant-negative form of Ets. These ®ndings indicated that Ets is a key factor that transduces EGF signals onto the hTERT promoter. The molecular mechanisms how EGF signals facilitate Ets activity remain unclear. One possible mechanism is up-regulation of Ets expression by EGF. However, we con®rmed that levels of Ets expression were not altered by the treatment with EGF (data not shown). Therefore, functional modi®cations of Ets such as protein phosphorylation may be essential for EGF-induced transactivation of hTERT. Phosphorylation of Ets family member has been reported to play a key role in transcriptional regulation of some genes, such as the matrix metalloproteinase gene and c-fos gene (Bosc et al., 2001; Babu et al., 2000) .
The Ets family mediates a variety of growth signals (Sementchenko and Watson, 2000) . Ets may therefore play a key role in telomerase regulation that is dependent on various growth factors other than EGF. We are currently investigating the eects of other growth factors on telomerase regulation and the role of Ets factor.
In summary, we concluded that EGF directly activates telomerase through the up-regulation of hTERT transcription, in which MAP kinase signaling pathways play major roles. We also demonstrated the role of Ets transcription factor in telomerase regulation. Our data support the notion that growth factors directly regulate telomerase via speci®c signal transduction pathways. Recently, several clinical trials are ongoing using signal transduction inhibitors as novel anticancer drugs. In particular, potential antitumor activity has been reported by EGFR tyrosine kinase inhibitors (Baselga and Averbuch, 2000) . Based on our results, EGFR tyrosine kinase inhibitors may block signalings for telomerase activation, which might be one mechanism of antitumor activity of these drugs. Further detailed analyses of the signal transduction pathways involved in telomerase regulation may provide important insight into the molecular mechanisms of telomerase activation as well as the development of novel anti-telomerase reagents.
Materials and methods
Cell cultures
NIH3T3 cells expressing the EGF receptor were isolated and cloned after the transfection with the human EGFR expression vector (Yamazaki et al., 1990) , and grown in DMEM with 6% FBS in the presence of 5% CO 2 at 378C. The vulvar cancer A-431 cells, breast cancer MCF-7 cells and cervical cancer ME180 cells that constitutively express high levels of EGF receptor were incubated in DMEM containing 10% FBS. To assay EGF induction, cells were starved for 24 h in serum-free DMEM, then incubated for various periods with EGF (Pepro Tech Inc. Rocky Hill, NJ, USA). Signal transduction pathways were assayed in cells incubated in media to which U0126 (Promega, Madison, WI, USA), Wortmannin (Sigma, St. Louis, MO, USA) and SB203580 (Promega) were added 1 h prior to EGF treatment.
TRAP assay
Telomeric Repeat Ampli®cation Protocol (TRAP) assays were performed using TRAPEZE telomerase detection kit (Invitrogen, NY, USA) according to the manufacturer's protocols.
RNA ± PCR analysis
The expression of hTERT mRNA was analysed by semiquantitative RT ± PCR ampli®cation as described (Nakamura et al., 1997) . The expression of mouse TERT mRNA was similarly analysed using the primer pairs, 5'-CAGA-CATTTCCTTTACTC-3' (clone 2a) and 5'-ACCATA-TACCTGCCAGGG-3' (clone 2b) (Martin-Rivera et al., 1998) .
In vitro kinase assay NIH3T3 and A-431 cells expressing EGFR were starved in serum-free medium for 24 h. Various concentrations of EGF were added to the dishes and incubated for 15 or 30 min at 378C. Cell pellets were then recovered and in vitro kinase assays were performed as described (Wang et al., 2000) . Reaction products were resolved by SDS ± PAGE.
Plasmid construction
The structures of hTERT promoter-luciferase constructs are shown in Figure 5a . Various lengths of promoter fragments were ampli®ed by PCR and inserted into pGL3-Basic (Promega) in the sense orientation. The names of the reporter constructs were assigned according to the 5'-end nucleotide numbers of inserted promoter sequences, upstream (7) or downstream (+) of the transcription start site . Mutant reporter plasmids containing mutations in two c-Myc site or ®ve Sp1 sites in the hTERT core promoter were named pGL3-181MycMT1+2 or pGL3-181Sp1MT1-5 as described . Mutant reporter plasmids containing mutations in putative initiator sites at +13 and +43 were constructed from pGL3-181, so that CGAGTTT-CAGGC at +13 was altered to CGAGTAATAGGC (pGL3-181 InrMT1) and GCACGTG at +43 was altered to GCACGAA (pGL3-181 InrMT2). A putative Ets site at 723 was also mutated in pGL3-32, so that TTCCTTTCCG at 723 was altered to TTAATTTAAG (pGL3-32 EtsMT). The expression plasmids encoding wild-type Ets-2 (pRK5-ets-2) or truncated Ets-2 with a dominant negative activity (pRK5-ets-2D1-328) were provided by Dr KE Boulukos (Universite de Nice, Faculte des Sciences, Nice, France) (Aperlo et al., 1996) .
Luciferase assays
Cells incubated in 24-well dishes were transfected with 0.4 mg of various reporter plasmids alone or together with 0.2 mg of eector plasmids using LipofectAMINE PLUS TM (Invitrogen Corp., Carlsbad, CA, USA) according to the manufacturer's protocol, then incubated in the absence or presence of EGF for 24 h. All experiments were performed at least three times with each plasmid and results represent average relative luciferase activity.
